Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Drug Profile

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Alternative Names: BMS-247616; CDHP/potassium-oxonate/tegafur; CIDU/potassium-oxonate/tegafur; Oteracil/tegafur/gimeracil; Potassium-oxonate/tegafur/CDHP; Potassium-oxonate/tegafur/CIDU; S-1; Tegafur/CDHP/potassium-oxonate; Tegafur/CIDU/potassium-oxonate; Tegafur/gimeracil/oteracil; Tegafur/potassium-oxonate/CDHP; Tegafur/potassium-oxonate/CIDU; Teysuno; TS-1; TS-ONE

Latest Information Update: 31 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Helsinki University Central Hospital; Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
  • Class Antineoplastics; Carboxylic acids; Furans; Halogenated hydrocarbons; Pyridines; Pyrimidinones; Small molecules; Triazines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase III Cervical cancer; Liver cancer; Oesophageal cancer; Squamous cell cancer; Uterine cancer
  • Phase II Gastrointestinal cancer; Renal cancer
  • No development reported Prostate cancer

Most Recent Events

  • 30 Jun 2021 Taiho Pharmaceutical completes phase II trials in Colorectal cancer (Inoperable/Unresectable, Metastatic disease, In the elderly, First-line therapy, Combination therapy) in Norway, Finland, Denmark (PO) (EudraCT2014-000394-39)
  • 19 Sep 2020 Interim adverse events and efficacy data from a phase II trial in Gastric cancer and Oesophageal cancer presented at the 45th European Society for Medical Oncology Congress (ESMO-2020)
  • 02 Jun 2020 Taiho pharmaceutical terminates a phase III trial in Squamous cell carcinoma of the lung (Late-stage disease; Recurrent) in Japan (UMIN000010396)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top